Overview

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Gem Pharmaceuticals
Treatments:
Doxorubicin